
    
      This study will evaluate the safety of agalsidase alfa in patients with Fabry disease.

      Patients diagnosed with Fabry disease who meet current Canadian guidelines for enzyme
      replacement therapy will be eligible to enroll in the study and will receive agalsidase alfa
      at a dose of 0.2 mg/kg body weight administered by an IV infusion over 40 minutes every week
      or every other week, based on previous treatment.

      Shire has implemented a change to the drug substance manufacturing process. Safety data will
      be collected in patients receiving product manufactured with this process. There are no
      changes to the drug product formulation, manufacturing site, manufacturing process, and
      container closure.
    
  